Published Date: 13 Mar 2023
The FDA approval request for CSU is based on data from a pair of Phase 3 trials in two different populations.
Read Full NewsThe 1-hour troponin pathway was safely implemented in a real-world study but did not impact workflow in busy emergency departments.
Edoxaban reduced ischemic stroke after intracranial hemorrhage in patients with AF, but excess hemorrhagic stroke and major bleeding offset the benefit.
A multicenter phase 3 trial has associated a cardiac myosin inhibitor with meaningful clinical benefit in nonobstructive HCM, for which there has been no effective therapies.
Tailored antibiotic therapy for infective endocarditis was associated with a significant reduction in treatment duration, according to an open-label multicenter trial.
1.
FDA Panel Endorses Capivasertib Use in Prostate Cancer
2.
Study finds 81% of cancer cures touted by TikTok videos are fake
3.
The top three drugs for multiple myeloma treatment upfront are four.
4.
More men with prostate cancer are avoiding unnecessary surgery
5.
After HSCT, a longer course of letermovir prophylaxis decreased the risk of cytomegalovirus infection.
1.
Patient Management After Personalized Surgical Oncology Reconstruction
2.
Drug Safety Surveillance for Emerging Immuno-Oncology Medication Risks
3.
Understanding Granulosa Cell Tumors: Symptoms, Diagnosis, and Treatments"
4.
7 Subtle Signs of Leukemia: How to Spot the Symptoms Early
5.
Essential Applications in Oncology in Daily Practice
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation